Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Histogen Inc. | cnat-ex322_9.htm |
EX-32.1 - EX-32.1 - Histogen Inc. | cnat-ex321_12.htm |
EX-31.2 - EX-31.2 - Histogen Inc. | cnat-ex312_7.htm |
EX-31.1 - EX-31.1 - Histogen Inc. | cnat-ex311_11.htm |
EX-10.35 - EX-10.35 - Histogen Inc. | cnat-ex1035_766.htm |
EX-10.34 - EX-10.34 - Histogen Inc. | cnat-ex1034_767.htm |
EX-10.33 - EX-10.33 - Histogen Inc. | cnat-ex1033_583.htm |
10-K - CNAT-10K-20161231 - Histogen Inc. | cnat-10k_20161231.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) |
Registration Statement (Form S-8 No. 333-211162) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan, |
(2) |
Registration Statement (Form S-8 No. 333-190134) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan, the Conatus Pharmaceuticals Inc. 2006 Equity Incentive Award Plan and the Conatus Pharmaceuticals Inc. 2013 Employee Stock Purchase Plan, and |
(3) |
Registration Statement (Form S-3 No. 333-198142) of Conatus Pharmaceuticals Inc.; |
of our report dated March 16, 2017, with respect to the financial statements of Conatus Pharmaceuticals Inc. included in this Annual Report (Form 10-K) of Conatus Pharmaceuticals Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP
San Diego, California
March 16, 2017